Additional Listing

IP2IPO Group PLC
11 May 2005



For immediate release                                              11 May 2005

                                  IP2IPO GROUP PLC
                            ('IP2IPO' or 'the Company')


IP2IPO is pleased to announce the launch of a placing of up to 2,157,837 new
ordinary shares of 10 pence each (the 'Placing Shares') for cash with
institutional investors, representing a maximum of 5 per cent. of the current
issued share capital of the Company (the 'Placing'). Further details of the
Placing will be announced in due course.

The proceeds of the Placing will be used to launch a new business within IP2IPO:
LifeUK. LifeUK will in-license life science intellectual property created by
medical researchers at universities with which IP2IPO already has partnerships,
other universities in the UK and similar academic and charitable research
institutions. LifeUK's objective is to further develop the intellectual property
which it in-licenses with a view to creating substantial value either by
subsequently licensing these development programmes to the pharmaceutical
industry or via the creation of new ventures.

The Placing Shares are being placed by Lehman Brothers International (Europe),
as sole bookrunner, and KBC Peel Hunt Ltd, as joint lead manager, and are being
placed conditional on admission to trading on the AIM Market of the London Stock
Exchange plc ('Admission'). Application has been made for Admission of the
Placing Shares and it is expected that Admission will become effective and
dealings in the Placing Shares will commence on 16 May 2005. The Placing Shares
to be allotted will be credited as fully paid and will rank pari passu in all
respects with the Company's existing ordinary shares of 10p each, including the
right to receive all dividends and distributions declared, made or paid on or
after the date of their allotment.

David Norwood, Chief Executive Officer commented, 'The launch of LifeUK
represents a significant strategic move for IP2IPO and considerably strengthens
and diversifies our business. In the academic arena, UK academics produce
ground-breaking medical research, while within industry, pharmaceutical
companies are increasingly looking for new sources of drug candidates to augment
their pipelines. LifeUK has been created to provide a channel from the lab bench
to industry which builds on the success that IP2IPO has already experienced
creating spin out companies under its long term university partnerships.'

Lehman Brothers International (Europe) and KBC Peel Hunt Ltd are each acting
exclusively for IP2IPO and are not acting on behalf of any other person and will
not be responsible to any person, other than IP2IPO, for providing the
protections afforded to their respective clients or for advising any such person
in connection with the Placing.

For more information please contact:

IP2IPO
David Norwood, Chief Executive Officer                           020 7489 5200

Buchanan Communications
Tim Anderson, Mark Court                                         020 7466 5000

Lehman Brothers International (Europe)
Stephen Pull, Mark Hutt                                          020 7102 1000

KBC Peel Hunt Ltd
Simon Hayes, Megan MacIntyre                                     020 7418 8900

Notes for editors

IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. The Company was founded in 2001 and
listed on the AIM Market of the London Stock Exchange plc in October 2003.
IP2IPO's first partnership was with the University of Oxford. In return for an
investment of £20 million, IP2IPO has acquired 50 per cent of the University of
Oxford's equity in spin-out companies and technology licenses based on
intellectual property created at the Chemistry Department until 2015. In
November 2003, IP2IPO created a £5 million seed capital fund for investing in
spin-out companies across the University of Oxford, not just those originating
within the Chemistry Department.

In March 2002, IP2IPO entered into a second long-term partnership with the
University of Southampton. Under the terms of this partnership, IP2IPO is
committed to working with the University of Southampton in the identification
and facilitation of spin-out companies from across the University of Southampton
and to investing £5 million in early-stage University of Southampton spin-out
companies over a four year period in return for equity stakes in those
companies. In addition, IP2IPO also received a 20 per cent stake in Southampton
Asset Management Limited, a company that has been formed to hold the
University's equity stakes in its spin-out companies. The partnership has a term
of at least 25 years.

IP2IPO entered into its third long-term partnership in May 2003 with King's
College London. IP2IPO will work with King's College London to help identify and
progress commercialisation opportunities as well as invest £5 million in seed
capital in spin-out companies from King's College London over a five year period
in return for equity stakes in those companies. In addition, IP2IPO will receive
20 per cent of King's College London's equity in spin-out companies and
technology licenses. The partnership has a term of 25 years.

In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel
Agricultural Products ('CNAP'), based at the University of York. CNAP is a
flagship research centre that specialises in plant and microbial gene discovery.
Under the terms of the partnership a new company, Amaethon Limited, has been
created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has
invested £1.15m in Amaethon Limited in return for a 40% equity stake in Amaethon
Limited (the remaining equity being owned by the University of York) and will
also invest in the spin-out companies based on CNAP's IP which Amaethon Limited
creates.

In June 2004, IP2IPO acquired Top Technology Ventures Limited, an investment
adviser to early stage technology funds. This combines IP2IPO's expertise in the
creation of new ventures based on world leading university IP with Top
Technology's focus on making early stage venture capital investments.

In January 2005, IP2IPO acquired Techtran, a company set up in 2002 to
commercialise university intellectual property under a long-term technology
commercialisation contract with the University of Leeds. Under the terms of the
contract Techtran receives a significant (30%) interest in spin-out companies
created and technology licences negotiated, in return for the provision of
technology transfer services to the University.

To date, 4 spin-out companies from the IP2IPO portfolio have listed on the AIM
Market of the London Stock Exchange plc: Offshore Hydrocarbon Mapping plc,
Synairgen plc, VASTox plc and Proximagen Neuroscience plc.

For more information please visit www.ip2ipo.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange